Hansa Biopharma AB
Nasdaq Stockholm · LEI 549300LLEO25ZJJ3NT91· Fiscal year 2025
Staff cost per employee
Not disclosed
Employees
Not disclosed
Quick read
- Revenue grew 29.7% year over year.
- Operating loss of $51.1M in 2025.
Last 3 years
Revenue
Operating income
See the share price on Google Finance ↗
Investor metrics
2025
- Operating margin
- -234.3%
- Net margin
- -240.3%
- Equity ratio
- -7.6%